NRX Pharmaceuticals Q3 EPS $(0.05) Beats $(0.21) Estimate, Sales $1.159M Miss $1.300M Estimate

Benzinga · 1d ago
NRX Pharmaceuticals (NASDAQ:NRXP) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.21) by 76.19 percent. This is a 81.48 percent increase over losses of $(0.27) per share from the same period last year. The company reported quarterly sales of $1.159 million which missed the analyst consensus estimate of $1.300 million by 10.85 percent. This is a 378.93 percent increase over sales of $242.000 thousand the same period last year.